- About 75 percent of all Hodgkin lymphoma patients are cured of their disease.
- In younger patients, the cure rate rises to 90 percent.
- The cure rate for stages I and II Hodgkin lymphoma is more than 95 percent.
Many Hodgkin lymphoma patients are cured after their initial treatment. For the smaller number of patients who have disease recurrence or relapse, additional treatment with chemotherapy, sometimes combined with stem cell transplantation, is often successful. A large number of these patients are cured or have long disease-free periods.
Relative Survival Rate
Relative survival compares (1) how long a person with a disease survives after being diagnosed to (2) how long a person without the disease lives. Survival statistics for Hodgkin lymphoma are usually reported as five-year survival rates:
- From 2003-2009, the five-year relative survival rate for people with Hodgkin lymphoma 87.6 percent.
- The five-year relative survival rate for children and adolescents younger than 15 years is 98.1 percent.
- An estimated 1,180 people will die from Hodgkin lymphoma in 2014.
Seven Prognosis Factors
Treatment outcomes (prognosis) for the disease in its advanced stages are influenced by seven factors, known as the International Prognostic Factors for Advanced Hodgkin Lymphoma. Higher risk is associated with these factors - the more factors present, the higher the risk. Doctors use these factors to help them decide how aggressive treatment should be. Risk increases if the patient:
- is male
- is 45 years or older
- has stage IV disease
- has hemoglobin levels in the blood of less than 10.5 grams per deciliter (g/dL)
- has a white cell count of 15,000 micrometers per liter (ÁL) or higher
- has a lymphocyte (a type of white cell) count of less than 600/ÁL and/or less than 8 percent of the total white cell count
- has albumin (a blood protein) levels of less than 4 g/dL
Treatment results and outcomes vary among patients. It's important to understand that the latest five-year survival statistics only reflect rates up to 2008. Recent and ongoing improvements in treatment and care may not be reflected in these rates. Newer treatment therapies, progress in stem cell transplantation, better supportive care and studies of new drugs in clinical trials are all contributing to improved outcomes and quality of life for people diagnosed with blood cancers.